FDA Accepts NDA for Vepdegestrant by Arvinas Operations
The FDA has accepted the New Drug Application (NDA) for Vepdegestrant (NDA219835) submitted by Arvinas Operations.
Therapeutic Area
Therapeutic area intelligence for Estrogen Receptor Modulator with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.